Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2022 Earnings Call Transcript

Lucas Ward: Okay. Clear. And then with respect to operating expenses, I was wondering if you could give a little color there? It looks like the sales and marketing was up sequentially quite a bit, although you were down a little on G&A. I’m wondering sort of what the trend is likely to be for 2023 on — well, just operating expenses overall. Let’s say we did $35 million this year, like do you expect that to grow in 2023? And if so, like roughly how much?

Brad Amman: Well, we’ve been focusing on our cash burn and operating expenses and G&A are obviously a big part of that. We had 180 employees in 2021, and now we ended the 2022, it’s about 160, and we are looking at other ways to save costs in terms of outsourcing some personnel to save some costs there. But we’re really focused on the cash burn. And if you look at the cash burn in first quarter, the whole quarter or first quarter of 2022, we burned $6.2 million of cash. And in the fourth quarter, we burned $3.3 million of cash. In third quarter, we burned $6 million. So we were down just about half of our burn, between third quarter and fourth quarter. So we saved $2.7 million. So we’re looking at things on a basis of what do we need to scale. We’re driving top line revenue and looking at the expense line item, so we can start to improve the bottom line as well.

Operator: There are no further questions at this time. I would like to turn the floor back over to Kirk Huntsman, Chairman and CEO, for closing comments.

Kirk Huntsman: Thank you, operator. I would like to thank everyone again for joining us on today’s call and for your continued interest in Vivos Therapeutics. We look forward to sharing our continued progress with you in the future. Thank you, and have a great evening.

Operator: Thank you. This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.